The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“The HER2 gene is amplified and overexpressed in about 25% of tumors, and patients with HER2-positive tumors have a poorer prognosis than other types of breast cancer; for example, approximately 80% of patients with invasive ductal carcinomas show HER2 amplification”
BackgroundTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Miller, A. J., & Mihm, M. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052166 · Cited by 1,339
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9844 · Cited by 758
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A., & Griffin, J. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2126 · Cited by 636
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Wooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 597
Retinoids, Retinoic Acid Receptors, and Cancer
Tang, X.-H., & Gudas, L. J. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130303 · Cited by 596
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
The biology and treatment of EML4-ALK non-small cell lung cancer
Sasaki, T., Rodig, S. J., Chirieac, L. R., & Jänne, P. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.002 · Cited by 555
Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., et al. (2007) · Nature · doi:10.1038/nature05697 · Cited by 474
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Cronin, M., Sangli, C., Liu, M.-L., Pho, M., Dutta, D., Nguyen, A., Jeong, J., Wu, J., Langone, K. C., & Watson, D. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076497 · Cited by 343
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 288
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Retinoic acid receptors and cancers
Soprano, D. R., Qin, P., & Soprano, K. J. (2004) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.012003.132407 · Cited by 270
Lin, R. J., & Evans, R. M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80322-6 · Cited by 232
Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Identification of serum biomarkers for colon cancer by proteomic analysis
Ward, D. G., Suggett, N., Cheng, Y., Wei, W., Johnson, H., Billingham, L. J., Ismail, T., Wakelam, M. J. O., Johnson, P. J., & Martin, A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603188 · Cited by 228
Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., & Gattermann, N. (2006) · Cancer · doi:10.1002/cncr.21552 · Cited by 224
Shi, H., Kong, X., Ribas, A., & Lo, R. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0140 · Cited by 222
Perez, E. A., Roche, P. C., Jenkins, R. B., Reynolds, C. A., Halling, K. C., Ingle, J. N., & Wold, L. E. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62329-x · Cited by 214
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Badgwell, B. D., Camp, E. R., Feig, B., Wolff, R. A., Eng, C., Ellis, L. M., & Cormier, J. N. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm508 · Cited by 180
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Duffy, M. J., & Crown, J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.110056 · Cited by 173
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Hamer, P. C. D. W. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop068 · Cited by 166
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2006) · Nature Biotechnology · doi:10.1038/nbt1234 · Cited by 161
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Khan, O. A., Fotheringham, S. A., Wood, V. H. J., Stimson, L., Zhang, C., Pezzella, F., Duvic, M. A., Kerr, D. J., & Thangue, N. B. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913912107 · Cited by 157
Self-citationKantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2135 · Cited by 149
HDAC inhibitor-based therapies and haematological malignancy
Stimson, L., Wood, V. H. J., Khan, O. A., Fotheringham, S. A., & Thangue, N. B. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn792 · Cited by 148
Evolving Treatment of Advanced Colon Cancer
Segal, N. H., & Saltz, L. B. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.041807.132435 · Cited by 148
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff, I. K., Cloughesy, T. F., & Mischel, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1992 · Cited by 146
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Self-citationErlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
Gridelli, C., Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., & Ciardiello, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-840 · Cited by 118
Zhou, D.-C., Kim, S. H., Ding, W., Schultz, C. L., Warrell, R. P., & Gallagher, R. E. (2002) · Blood · doi:10.1182/blood.v99.4.1356 · Cited by 118
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
Azorsa, D. O., Gonzales, I. M., Basu, G. D., Choudhary, A. K., Arora, S., Bisanz, K. M., Kiefer, J., Henderson, M. C., Trent, J. M., Hoff, D. D. V., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-43 · Cited by 115
Costs of cancer care in the USA: a descriptive review
Yabroff, K. R., Warren, J. L., & Brown, M. L. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0978 · Cited by 108
Systematic Review of HER2 Breast Cancer Testing
Cuadros, M., & Villegas, R. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318169fc1c · Cited by 84
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
Mullenders, J., & Bernards, R. (2009) · Oncogene · doi:10.1038/onc.2009.295 · Cited by 82
Phillips, K. A., Marshall, D. A., Haas, J. S., Elkin, E. B., Liang, S., Hassett, M. J., Ferrusi, I. L., Brock, J. E., & Bebber, S. L. V. (2009) · Cancer · doi:10.1002/cncr.24574 · Cited by 74
NICE and the challenge of cancer drugs
Raftery, J. P. (2009) · BMJ · doi:10.1136/bmj.b67 · Cited by 72
Colorectal cancer in review: the role of the EGFR pathway
Saif, M. W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003593962 · Cited by 67
Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
Breccia, M., & Alimena, G. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.08.031 · Cited by 64
The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.
Diverio, D., Riccioni, R., Mandelli, F., & Coco, F. L. (1995) · PubMed · Cited by 40
Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 36
PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
Hutchinson, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.143 · Cited by 32
Trastuzumab resistance: all roads lead to SRC
Muthuswamy, S. K. (2011) · Nature Medicine · doi:10.1038/nm0411-416 · Cited by 29
Santos, M. D. L., Zambrano, A., Sánchez‐Pacheco, A., & Aranda, A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0151 · Cited by 29
Proteasome and HDAC: who's zooming who?
McConkey, D. J. (2010) · Blood · doi:10.1182/blood-2010-04-278507 · Cited by 25
Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective
Fine, B. M., & Amler, L. C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.9 · Cited by 19
Terasawa, T., Dahabreh, I. J., & Trikalinos, T. A. (2010) · PLoS Currents · doi:10.1371/currents.rrn1204 · Cited by 19
Emerging companion diagnostics for cancer drugs
August, J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3173 · Cited by 16
Wodarz, D. (2010) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2009.2179 · Cited by 14
Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients
Santini, D., Pantano, F., Vincenzi, B., Loupakis, F., Caraglia, M., Falcone, A., & Tonini, G. (2008) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2008.06.008 · Cited by 4
Fuerst, M. L. (2006) · Oncology Times · doi:10.1097/01.cot.0000295043.51908.95 · Cited by 4
Cited by
Zwanenburg, A., Vallières, M., Abdalah, M. A., Aerts, H. J. W. L., Andrearczyk, V., Apte, A., Ashrafinia, S., Bakas, S., Beukinga, R. J., Boellaard, R., et al. (2020) · Radiology · doi:10.1148/radiol.2020191145 · Cited by 4,177
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
Skrede, O.-J., De Raedt, S., Kleppe, A., Hveem, T. S., Liestøl, K., Maddison, J., Askautrud, H. A., Pradhan, M., Nesheim, J. A., Albregtsen, F., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32998-8 · Cited by 627
Self-citationCirculating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Metadata
- Authors
- La Thangue, N. B., & Kerr, D. J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2011-08-23
- Volume
- 8
- Issue
- 10
- Pages
- 587-596
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2088905520
- Cited by
- 332
- References
- 88
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.